Arabic Arabic English English French French German German
dark

Amylyx Scores $135 Million for ALS Drug with Hopes for Quick Approval

The Boston-based company announced an infusion of $135 million in Series C funds to support the late-stage development of its lead candidate, AMX0035, for amyotrophic lateral sclerosis. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

The environmental toll of disposable masks

Next Post

XPhyto Signs Transformative Acquisition Agreement With 3a-Diagnostics, to Enter Hi-Tech Biosensor Market and Expand Its Diagnostic Product Portfolio

Related Posts
Total
0
Share